Abbott Faces Calls For Compulsory License For Norvis

Law360, New York (May 13, 2004, 12:00 AM EDT) -- Abbott Laboratories’ nearly fivefold increase on its AIDS drug Norvis has prompted calls from government officials for a compulsory license for a generic version of the drug before its patent expiration, the Wall Street Journal reported.

In December, Abbott Labs raised the wholesale price for a month's worth of the protease inhibitor Norvir, widely used in small doses to boost the potency of some AIDS combination-drug therapies, to $265 from $54.

The move caused an avalanche of protests from AIDS activists, who have demanded a public...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.